Drug Profile
Research programme: beta-2 adrenoceptor agonists - GlaxoSmithKline/Innoviva
Alternative Names: 293521; 324279; 849117; GSK 293521; GSK 324279; GSK 849117; Horizon programme; LABA programme - GlaxoSmithKline/Innoviva; RELOVAIR programme; THRX-666558Latest Information Update: 23 Nov 2016
Price :
$50
*
At a glance
- Originator Theravance
- Developer GlaxoSmithKline; Innoviva
- Class Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 19 Mar 2010 No development reported - Preclinical for Asthma in USA (Inhalation)
- 19 Mar 2010 No development reported - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
- 19 Mar 2010 The generation of development candidates from this research programme appears to have ceased